Sort by
Refine Your Search
-
Listed
-
Country
-
Field
-
RTG3120 on Biomolecular Condensates ( https://dresdencondensates.org ). Each PhD project is part of an interdisciplinary framework that includes shared training activities, and supervision by
-
is actively promoted by the Faculty of Science, fostered under the University-wide six Interdisciplinary Labs (https://interdisciplinary-research.hkbu.edu.hk/), and supported by state-of-the-art
-
, see https://www.ntnu.edu/studies/phiot . As a PhD Candidate, you are obligated to participate in an organized PhD program during the employment period. A condition of appointment is that you are
-
. The Microscopy Facility Director will interface closely with both internal and external members of the ODBI community. Candidates should have a PhD in a related field. Candidates without a PhD, but with an
-
chemistry Researcher Profile First Stage Researcher (R1) Positions PhD Positions Application Deadline 31 May 2026 - 00:00 (Europe/London) Country United Kingdom Type of Contract To be defined Job Status Full
-
The Center for Molecular Bioengineering (B CUBE) is an interdisciplinary research center focusing on three research dimensions: Bio-prospecting, BioNano Tools, and Biomimetic Materials (see https
-
. ------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------...
-
Technology » Energy technology Technology » Interface technology Technology » Nanotechnology Physics » Solid state physics Physics » Chemical physics Researcher Profile Recognised Researcher (R2) Positions PhD
-
tracer kinetics; thermography; BAT thermogenesis; tissue chemistry; ELISA; Glucose and insulin tolerance tests Interface with companies and Penn IT to troubleshoot equipment and software issues, often
-
: Marcin Poręba, PhD, DSc, Prof. of WUST. The PACMAN project aims to develop a new class of antibody–drug conjugates (ADCs) that do not require internalization and are selectively activated extracellularly